http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 04 Mar 2026 08:00:56 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/FDA+clears+Bayer%27s+MEDRAD+MRXperion+system+for+7T+MRI+compatibility/26107427.html <p>Bayer announced the U.S. Food and Drug Administration granted 510(k) clearance for expanded capabilities of its MEDRAD MRXperion Magnetic Resonance injection system. The clearance extends the device's compatibility to support MRI scanners with magnetic fields up to 7 Tesla.</p> <p>The updated clearance also introduces Imaging Scanner Interface 2 capability, which enables communication between the injector and scanner system. This feature is designed to help coordinate exam procedures and support operational efficiency in radiology departments.</p> <p>MRXperion is a piston-technology power injector used to deliver contrast agents and saline during contrast-enhanced MRI procedures. The system was previously cleared for lower magnetic field strengths but http://www.streetinsider.com/FDA/FDA+clears+Bayer%27s+MEDRAD+MRXperion+system+for+7T+MRI+compatibility/26107427.html Wed, 04 Mar 2026 08:00:56 -0500 A.06822034 BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/FDA/FDA+clears+Bayer%27s+MEDRAD+MRXperion+system+for+7T+MRI+compatibility/26107427.html <p>Bayer announced the U.S. Food and Drug Administration granted 510(k) clearance for expanded capabilities of its MEDRAD MRXperion Magnetic Resonance injection system. The clearance extends the device's compatibility to support MRI scanners with magnetic fields up to 7 Tesla.</p> <p>The updated clearance also introduces Imaging Scanner Interface 2 capability, which enables communication between the injector and scanner system. This feature is designed to help coordinate exam procedures and support operational efficiency in radiology departments.</p> <p>MRXperion is a piston-technology power injector used to deliver contrast agents and saline during contrast-enhanced MRI procedures. The system was previously cleared for lower magnetic field strengths but http://www.streetinsider.com/FDA/FDA+clears+Bayer%27s+MEDRAD+MRXperion+system+for+7T+MRI+compatibility/26107427.html Wed, 04 Mar 2026 08:00:56 -0500 A.06822034 BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/FDA/FDA+clears+Bayer%27s+MEDRAD+MRXperion+system+for+7T+MRI+compatibility/26107427.html <p>Bayer announced the U.S. Food and Drug Administration granted 510(k) clearance for expanded capabilities of its MEDRAD MRXperion Magnetic Resonance injection system. The clearance extends the device's compatibility to support MRI scanners with magnetic fields up to 7 Tesla.</p> <p>The updated clearance also introduces Imaging Scanner Interface 2 capability, which enables communication between the injector and scanner system. This feature is designed to help coordinate exam procedures and support operational efficiency in radiology departments.</p> <p>MRXperion is a piston-technology power injector used to deliver contrast agents and saline during contrast-enhanced MRI procedures. The system was previously cleared for lower magnetic field strengths but http://www.streetinsider.com/FDA/FDA+clears+Bayer%27s+MEDRAD+MRXperion+system+for+7T+MRI+compatibility/26107427.html Wed, 04 Mar 2026 08:00:56 -0500 A.06822034 BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/FDA/FDA+clears+Bayer%27s+MEDRAD+MRXperion+system+for+7T+MRI+compatibility/26107427.html <p>Bayer announced the U.S. Food and Drug Administration granted 510(k) clearance for expanded capabilities of its MEDRAD MRXperion Magnetic Resonance injection system. The clearance extends the device's compatibility to support MRI scanners with magnetic fields up to 7 Tesla.</p> <p>The updated clearance also introduces Imaging Scanner Interface 2 capability, which enables communication between the injector and scanner system. This feature is designed to help coordinate exam procedures and support operational efficiency in radiology departments.</p> <p>MRXperion is a piston-technology power injector used to deliver contrast agents and saline during contrast-enhanced MRI procedures. The system was previously cleared for lower magnetic field strengths but http://www.streetinsider.com/FDA/FDA+clears+Bayer%27s+MEDRAD+MRXperion+system+for+7T+MRI+compatibility/26107427.html Wed, 04 Mar 2026 08:00:56 -0500 A.06822034 BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/FDA/FDA+clears+Bayer%27s+MEDRAD+MRXperion+system+for+7T+MRI+compatibility/26107427.html <p>Bayer announced the U.S. Food and Drug Administration granted 510(k) clearance for expanded capabilities of its MEDRAD MRXperion Magnetic Resonance injection system. The clearance extends the device's compatibility to support MRI scanners with magnetic fields up to 7 Tesla.</p> <p>The updated clearance also introduces Imaging Scanner Interface 2 capability, which enables communication between the injector and scanner system. This feature is designed to help coordinate exam procedures and support operational efficiency in radiology departments.</p> <p>MRXperion is a piston-technology power injector used to deliver contrast agents and saline during contrast-enhanced MRI procedures. The system was previously cleared for lower magnetic field strengths but http://www.streetinsider.com/FDA/FDA+clears+Bayer%27s+MEDRAD+MRXperion+system+for+7T+MRI+compatibility/26107427.html Wed, 04 Mar 2026 08:00:56 -0500 A.06822034 BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/FDA/FDA+clears+Bayer%27s+MEDRAD+MRXperion+system+for+7T+MRI+compatibility/26107427.html <p>Bayer announced the U.S. Food and Drug Administration granted 510(k) clearance for expanded capabilities of its MEDRAD MRXperion Magnetic Resonance injection system. The clearance extends the device's compatibility to support MRI scanners with magnetic fields up to 7 Tesla.</p> <p>The updated clearance also introduces Imaging Scanner Interface 2 capability, which enables communication between the injector and scanner system. This feature is designed to help coordinate exam procedures and support operational efficiency in radiology departments.</p> <p>MRXperion is a piston-technology power injector used to deliver contrast agents and saline during contrast-enhanced MRI procedures. The system was previously cleared for lower magnetic field strengths but http://www.streetinsider.com/FDA/FDA+clears+Bayer%27s+MEDRAD+MRXperion+system+for+7T+MRI+compatibility/26107427.html Wed, 04 Mar 2026 08:00:56 -0500 A.06822034 BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Press+Releases/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html <ul class="bwlistdisc"> <li> <b><i>Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions</i></b> </li> <li> <b><i>Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T</i></b> </li> <li> <b><i>Imaging Scanner Interface 2 synchronizes contrast injection with MR scanning to simplify operator workflow</i></b> </li> </ul> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. </p><p> This updated clearance expands MRXperion’s labeled field strength compatibility http://www.streetinsider.com/Press+Releases/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 BAYN BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Press+Releases/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html <ul class="bwlistdisc"> <li> <b><i>Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions</i></b> </li> <li> <b><i>Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T</i></b> </li> <li> <b><i>Imaging Scanner Interface 2 synchronizes contrast injection with MR scanning to simplify operator workflow</i></b> </li> </ul> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. </p><p> This updated clearance expands MRXperion’s labeled field strength compatibility http://www.streetinsider.com/Press+Releases/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 BAYN BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Press+Releases/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html <ul class="bwlistdisc"> <li> <b><i>Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions</i></b> </li> <li> <b><i>Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T</i></b> </li> <li> <b><i>Imaging Scanner Interface 2 synchronizes contrast injection with MR scanning to simplify operator workflow</i></b> </li> </ul> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. </p><p> This updated clearance expands MRXperion’s labeled field strength compatibility http://www.streetinsider.com/Press+Releases/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 BAYN BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Press+Releases/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html <ul class="bwlistdisc"> <li> <b><i>Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions</i></b> </li> <li> <b><i>Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T</i></b> </li> <li> <b><i>Imaging Scanner Interface 2 synchronizes contrast injection with MR scanning to simplify operator workflow</i></b> </li> </ul> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. </p><p> This updated clearance expands MRXperion’s labeled field strength compatibility http://www.streetinsider.com/Press+Releases/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 BAYN BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Press+Releases/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html <ul class="bwlistdisc"> <li> <b><i>Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions</i></b> </li> <li> <b><i>Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T</i></b> </li> <li> <b><i>Imaging Scanner Interface 2 synchronizes contrast injection with MR scanning to simplify operator workflow</i></b> </li> </ul> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. </p><p> This updated clearance expands MRXperion’s labeled field strength compatibility http://www.streetinsider.com/Press+Releases/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 BAYN BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Press+Releases/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html <ul class="bwlistdisc"> <li> <b><i>Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions</i></b> </li> <li> <b><i>Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T</i></b> </li> <li> <b><i>Imaging Scanner Interface 2 synchronizes contrast injection with MR scanning to simplify operator workflow</i></b> </li> </ul> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. </p><p> This updated clearance expands MRXperion’s labeled field strength compatibility http://www.streetinsider.com/Press+Releases/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 BAYN BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Press+Releases/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html <ul class="bwlistdisc"> <li> <b><i>Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions</i></b> </li> <li> <b><i>Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T</i></b> </li> <li> <b><i>Imaging Scanner Interface 2 synchronizes contrast injection with MR scanning to simplify operator workflow</i></b> </li> </ul> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. </p><p> This updated clearance expands MRXperion’s labeled field strength compatibility http://www.streetinsider.com/Press+Releases/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 BAYN BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Business+Wire/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html <ul class="bwlistdisc"> <li> <b><i>Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions</i></b> </li> <li> <b><i>Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T</i></b> </li> <li> <b><i>Imaging Scanner Interface 2 synchronizes contrast injection with MR scanning to simplify operator workflow</i></b> </li> </ul> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. </p><p> This updated clearance expands MRXperion’s labeled field strength compatibility http://www.streetinsider.com/Business+Wire/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 BAYN BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Business+Wire/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html <ul class="bwlistdisc"> <li> <b><i>Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions</i></b> </li> <li> <b><i>Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T</i></b> </li> <li> <b><i>Imaging Scanner Interface 2 synchronizes contrast injection with MR scanning to simplify operator workflow</i></b> </li> </ul> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. </p><p> This updated clearance expands MRXperion’s labeled field strength compatibility http://www.streetinsider.com/Business+Wire/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 BAYN BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Business+Wire/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html <ul class="bwlistdisc"> <li> <b><i>Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions</i></b> </li> <li> <b><i>Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T</i></b> </li> <li> <b><i>Imaging Scanner Interface 2 synchronizes contrast injection with MR scanning to simplify operator workflow</i></b> </li> </ul> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. </p><p> This updated clearance expands MRXperion’s labeled field strength compatibility http://www.streetinsider.com/Business+Wire/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 BAYN BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Business+Wire/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html <ul class="bwlistdisc"> <li> <b><i>Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions</i></b> </li> <li> <b><i>Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T</i></b> </li> <li> <b><i>Imaging Scanner Interface 2 synchronizes contrast injection with MR scanning to simplify operator workflow</i></b> </li> </ul> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. </p><p> This updated clearance expands MRXperion’s labeled field strength compatibility http://www.streetinsider.com/Business+Wire/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 BAYN BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Business+Wire/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html <ul class="bwlistdisc"> <li> <b><i>Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions</i></b> </li> <li> <b><i>Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T</i></b> </li> <li> <b><i>Imaging Scanner Interface 2 synchronizes contrast injection with MR scanning to simplify operator workflow</i></b> </li> </ul> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. </p><p> This updated clearance expands MRXperion’s labeled field strength compatibility http://www.streetinsider.com/Business+Wire/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 BAYN BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Business+Wire/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html <ul class="bwlistdisc"> <li> <b><i>Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions</i></b> </li> <li> <b><i>Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T</i></b> </li> <li> <b><i>Imaging Scanner Interface 2 synchronizes contrast injection with MR scanning to simplify operator workflow</i></b> </li> </ul> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. </p><p> This updated clearance expands MRXperion’s labeled field strength compatibility http://www.streetinsider.com/Business+Wire/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 BAYN BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Business+Wire/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html <ul class="bwlistdisc"> <li> <b><i>Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions</i></b> </li> <li> <b><i>Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T</i></b> </li> <li> <b><i>Imaging Scanner Interface 2 synchronizes contrast injection with MR scanning to simplify operator workflow</i></b> </li> </ul> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. </p><p> This updated clearance expands MRXperion’s labeled field strength compatibility http://www.streetinsider.com/Business+Wire/New+FDA+510%28k%29+Clearance+Expands+Bayer%E2%80%99s+MEDRAD%C2%AE+MRXperion+MR+Injection+System+Support+Across+Diverse+Range+of+MR+Environments/26107405.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 BAYN BAYN BAYRY BAYZF O.00258640 O.20026344 http://www.streetinsider.com/Corporate+News/Bayer+reports+phase+I+results+for+prostate+cancer+therapy/26078937.html <p>Bayer announced results from its Phase I PAnTHa study evaluating ²²⁵Ac-PSMA-Trillium (BAY 3563254), an investigational targeted alpha therapy for patients with advanced metastatic castration-resistant prostate cancer.</p><p>The dose-escalation study identified an expansion dose, with at least 80% of patients achieving a PSA50 response at that dose level. Data were presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.</p><p>The study enrolled 50 patients across four dose levels, with 80% completing all four cycles of treatment administered intravenously every six weeks. No dose-limiting toxicities or treatment-related deaths occurred. Common treatment-emergent adverse events included dry mouth, fatigue and http://www.streetinsider.com/Corporate+News/Bayer+reports+phase+I+results+for+prostate+cancer+therapy/26078937.html Fri, 27 Feb 2026 12:48:50 -0500 BAYN BAYRY BAYZF http://www.streetinsider.com/Corporate+News/Bayer+reports+phase+I+results+for+prostate+cancer+therapy/26078937.html <p>Bayer announced results from its Phase I PAnTHa study evaluating ²²⁵Ac-PSMA-Trillium (BAY 3563254), an investigational targeted alpha therapy for patients with advanced metastatic castration-resistant prostate cancer.</p><p>The dose-escalation study identified an expansion dose, with at least 80% of patients achieving a PSA50 response at that dose level. Data were presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.</p><p>The study enrolled 50 patients across four dose levels, with 80% completing all four cycles of treatment administered intravenously every six weeks. No dose-limiting toxicities or treatment-related deaths occurred. Common treatment-emergent adverse events included dry mouth, fatigue and http://www.streetinsider.com/Corporate+News/Bayer+reports+phase+I+results+for+prostate+cancer+therapy/26078937.html Fri, 27 Feb 2026 12:48:50 -0500 BAYN BAYRY BAYZF http://www.streetinsider.com/Corporate+News/Bayer+reports+phase+I+results+for+prostate+cancer+therapy/26078937.html <p>Bayer announced results from its Phase I PAnTHa study evaluating ²²⁵Ac-PSMA-Trillium (BAY 3563254), an investigational targeted alpha therapy for patients with advanced metastatic castration-resistant prostate cancer.</p><p>The dose-escalation study identified an expansion dose, with at least 80% of patients achieving a PSA50 response at that dose level. Data were presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.</p><p>The study enrolled 50 patients across four dose levels, with 80% completing all four cycles of treatment administered intravenously every six weeks. No dose-limiting toxicities or treatment-related deaths occurred. Common treatment-emergent adverse events included dry mouth, fatigue and http://www.streetinsider.com/Corporate+News/Bayer+reports+phase+I+results+for+prostate+cancer+therapy/26078937.html Fri, 27 Feb 2026 12:48:50 -0500 BAYN BAYRY BAYZF http://www.streetinsider.com/Press+Releases/Bayer+Reports+Results+for+the+Investigational+Targeted+Radionuclide+Therapy+%C2%B2%C2%B2%E2%81%B5Ac-PSMA-Trillium+in+Advanced+Metastatic+Prostate+Cancer/26078895.html <ul class="bwlistdisc"> <li>  225Ac-PSMA-Trillium (BAY 3563254) is an investigational targeted alpha therapy (TAT) being developed for patients with advanced metastatic castration-resistant prostate cancer (mCRPC) </li> <li> Data from PAnTHa, the global Phase I first-in-human, dose-escalation study were presented during the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA </li> <li> Data support advancing 225Ac-PSMA-Trillium to the next phase of development </li> <li> Prostate cancer is the second most common diagnosed cancer in men1, with less than three years median survival among metastatic patients, who have developed castration-resistance2 </li> <li> TAT is a strategic pillar of precision oncology at Bayer, with the potential to shift the treatment paradigm for patients </li> </ul><p> <b>Not http://www.streetinsider.com/Press+Releases/Bayer+Reports+Results+for+the+Investigational+Targeted+Radionuclide+Therapy+%C2%B2%C2%B2%E2%81%B5Ac-PSMA-Trillium+in+Advanced+Metastatic+Prostate+Cancer/26078895.html Fri, 27 Feb 2026 12:43:00 -0500 BAYN BAYN BAYRY BAYZF O.00258640 http://www.streetinsider.com/Press+Releases/Bayer+Reports+Results+for+the+Investigational+Targeted+Radionuclide+Therapy+%C2%B2%C2%B2%E2%81%B5Ac-PSMA-Trillium+in+Advanced+Metastatic+Prostate+Cancer/26078895.html <ul class="bwlistdisc"> <li>  225Ac-PSMA-Trillium (BAY 3563254) is an investigational targeted alpha therapy (TAT) being developed for patients with advanced metastatic castration-resistant prostate cancer (mCRPC) </li> <li> Data from PAnTHa, the global Phase I first-in-human, dose-escalation study were presented during the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA </li> <li> Data support advancing 225Ac-PSMA-Trillium to the next phase of development </li> <li> Prostate cancer is the second most common diagnosed cancer in men1, with less than three years median survival among metastatic patients, who have developed castration-resistance2 </li> <li> TAT is a strategic pillar of precision oncology at Bayer, with the potential to shift the treatment paradigm for patients </li> </ul><p> <b>Not http://www.streetinsider.com/Press+Releases/Bayer+Reports+Results+for+the+Investigational+Targeted+Radionuclide+Therapy+%C2%B2%C2%B2%E2%81%B5Ac-PSMA-Trillium+in+Advanced+Metastatic+Prostate+Cancer/26078895.html Fri, 27 Feb 2026 12:43:00 -0500 BAYN BAYN BAYRY BAYZF O.00258640